|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Telmisartan#Pharmacology]] |
| | IUPAC_name = <nowiki>2-[4-[[4-methyl-6-(1-methylbenzoimidazol-2-yl)-</nowiki><br /><nowiki>2-propyl-benzoimidazol-1-yl]methyl]phenyl]</nowiki><br /><nowiki>benzoic acid</nowiki>
| |
| | image = Telmisartan.png
| |
| | width = 180px
| |
| | CAS_number = 144701-48-4
| |
| | ATC_prefix = C09
| |
| | ATC_suffix = CA07
| |
| | PubChem = 65999
| |
| | DrugBank = APRD01247
| |
| | C=33 | H=30 | N=4 | O=2
| |
| | molecular_weight = 514.617 g/mol
| |
| | bioavailability = 42–100%
| |
| | protein_bound = ≥99.5%
| |
| | metabolism = Minimal hepatic
| |
| | elimination_half-life = 24 hours
| |
| | excretion = Faecal 97%
| |
| | pregnancy_category = D <small>([[Australia|Au]])</small>, D <small>([[United States|U.S.]])</small>
| |
| | legal_status = S4 <small>(Au)</small>, POM <small>([[United Kingdom|UK]])</small>, ℞-only <small>(U.S.)</small>
| |
| | routes_of_administration = Oral
| |
| }}
| |
| {{SI}}
| |
| {{CMG}}
| |
| __NOTOC__
| |
| {{Editor Join}}
| |
| | |
| ==[[Telmisartan (patient information)|For patient information, click here]]==
| |
| | |
| ==Overview==
| |
| '''Telmisartan''' ([[International Nonproprietary Name|INN]]) ({{pronEng|tɛlmɪˈsɑrtən}}) is an [[angiotensin II receptor antagonist]] (ARB) used in the management of [[hypertension]]. It is marketed under the trade names '''Micardis''' ([[Boehringer Ingelheim]]) and '''Pritor''' or '''Kinzal''' ([[Bayer Schering Pharma]]).
| |
| | |
| ==Pharmacology==
| |
| Generally, [[angiotensin II receptor blocker]]s (ARBs) such as telmisartan bind to the [[Angiotensin receptor|angiotensin II type 1 (AT<sub>1</sub>) receptors]] with high affinity, causing inhibition of the action of [[Angiotensin#Angiotensin II|angiotensin II]] on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure.
| |
|
| |
| New studies suggest that telmisartan may also have [[Peroxisome proliferator-activated receptor|PPARγ]] agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. In India it is available in the name of '''Telma''' by Glenmark Pharma according to '''www.sureshjain.com'''.
| |
| | |
| ==Clinical use==
| |
| {{dablink|Main article: [[Angiotensin II receptor antagonist]]}}
| |
| In India RANBAXY also markets it under the name of 'Teleact 20 mg"
| |
| | |
| ==External links==
| |
| * http://www.pritor.com
| |
| * http://www.pslgroup.com/dg/e6dce.htm
| |
| | |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| {{SIB}}
| |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Drugs]]
| |
| | |
| [[nl:Telmisartan]]
| |
| [[pl:Telmisartan]]
| |
| [[pt:Telmisartan]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |